TABLE 6

Association of eotaxin with type 2 diabetes and IGT (multiple logistic regression models)

Eotaxin (pg/ml)Quartile 1 (≤40.64)Quartile 2 (>40.64/≤74.35)Quartile 3 (>74.35/≤106.80)Quartile 4 (>106.80)P for trend
Type 2 diabetes vs. control subjects
Model 11.01.27 (0.75–2.13)1.14 (0.67–1.92)1.41 (0.85–2.36)NS
Model 21.01.12 (0.63–1.98)1.15 (0.65–2.04)1.27 (0.72–2.23)NS
Model 31.00.98 (0.53–1.79)1.06 (0.57–1.96)1.19 (0.66–2.17)NS
Model 41.00.91 (0.49–1.70)1.02 (0.55–1.92)1.15 (0.62–2.14)NS
IGT vs. control subjects
Model 11.01.12 (0.68–1.86)0.98 (0.59–1.63)1.14 (0.69–1.88)NS
Model 21.00.99 (0.58–1.68)0.99 (0.58–1.68)1.08 (0.64–1.82)NS
Model 31.00.92 (0.53–1.61)1.00 (0.57–1.75)1.05 (0.61–1.83)NS
Model 41.00.87 (0.49–1.54)0.95 (0.54–1.68)0.98 (0.56–1.73)NS
  • Data are ORs (95% CI) for association of type 2 diabetes or IGT with eotaxin. Quartiles are based on data from normoglycemic control subjects. Model 1: crude; model 2: adjusted for BMI; model 3: adjusted for BMI, sex, age, hypertension, LDL cholesterol, HDL cholesterol, and uric acid; model 4: model 3 with additional adjustment for log-CRP and log-IL-6.